Nombre del producto:1,1-Dimethylethyl (2S)-2-[(2S)-4-bromo-5-chloro-6-fluoro-2,3-dihydro-2-phenyl-2-benzofuranyl]-1-pyrrolidinecarboxylate

IUPAC Name:tert-butyl (2S)-2-[(2S)-4-bromo-5-chloro-6-fluoro-2-phenyl-2,3-dihydro-1-benzofuran-2-yl]pyrrolidine-1-carboxylate

CAS:2711862-49-4
Fórmula molecular:C23H24BrClFNO3
Pureza:95%+
Número de catálogo:CM1077690
Peso molecular:496.8

Unidad de embalaje Stock disponible Precio($) Cantidad

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :2711862-49-4
Fórmula molecular:C23H24BrClFNO3
Punto de fusión:-
Código de sonrisas:C(OC(C)(C)C)(=O)N1[C@]([C@]2(CC=3C(O2)=CC(F)=C(Cl)C3Br)C4=CC=CC=C4)(CCC1)[H]
Densidad:1.439±0.06 g/cm3
Número de catálogo:CM1077690
Peso molecular:496.8
Punto de ebullición:528.9±50.0 °C
Nº Mdl:
Almacenamiento:

Category Infos

Benzofurans
Benzofuran is an aromatic heterocyclic organic compound with the chemical formula C8H6O. It is a colorless oily liquid at room temperature with an aromatic odor. Benzofuran can be volatilized with water vapor and can be decomposed by potassium permanganate and other oxidants. It is an intermediate for the preparation of amiodarone and indene resin. Benzofuran derivatives are important pharmaceutical intermediates.
Benzofuran | C8H6O | CID 9223 -Chemenu
Benzofuran | C8H6O | CID 9223 |Where to Buy Benzofurans
Benzofuran is the heterocyclic compound consisting of fused benzene and furan rings. This colourless liquid is a component of coal tar.Benzofuran is extracted from coal tar. It is also obtained by dehydrogenation of 2-ethylphenol.

Column Infos

IAG933
IAG933 is a potent, selective, and first-in-class inhibitor from Novartis that directly inhibits the protein-protein interaction (PPI) between YAP/TAZ and TEAD. By blocking this PPI, IAG933 interferes with oncogenic functions downstream of the Hippo signaling pathway, particularly in mesothelioma and other tumors with NF2 loss-of-function mutations or YAP/TAZ fusions. This inhibition reduces transcriptional activity and induces cell death in cancer cells, leading to significant tumor regressions in xenograft models. Additionally, combining IAG933 preclinically with other targeted therapies (i.e., RTK, KRAS-mutant selective, and MAPK inhibitors) shows promise for improving the efficacy and durability of treatment responses. IAG933 is currently being evaluated in a Ph. I trial (NCT04857372) for solid tumors with Hippo pathway alterations.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.